Equities analysts forecast that Cryoport, Inc. (NASDAQ:CYRX – Get Rating) will post earnings of ($0.14) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Cryoport’s earnings, with estimates ranging from ($0.23) to ($0.07). Cryoport posted earnings of ($0.16) per share in the same quarter last year, which indicates a positive year over year growth rate of 12.5%. The business is expected to report its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Cryoport will report full year earnings of ($0.67) per share for the current financial year, with EPS estimates ranging from ($0.91) to ($0.51). For the next year, analysts expect that the business will post earnings of ($0.20) per share, with EPS estimates ranging from ($0.68) to $0.18. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Cryoport.
Cryoport (NASDAQ:CYRX – Get Rating) last issued its quarterly earnings results on Thursday, May 5th. The consumer goods maker reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.11). The firm had revenue of $52.30 million for the quarter, compared to analyst estimates of $52.86 million. Cryoport had a negative net margin of 128.78% and a negative return on equity of 13.79%. The company’s revenue was down 1.9% compared to the same quarter last year. During the same period last year, the company earned ($0.13) EPS.
Cryoport stock traded up $3.13 during trading hours on Friday, reaching $26.22. 427,698 shares of the company’s stock traded hands, compared to its average volume of 539,659. The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of -4.29 and a beta of 1.30. The company has a debt-to-equity ratio of 0.68, a quick ratio of 14.48 and a current ratio of 14.98. Cryoport has a fifty-two week low of $19.82 and a fifty-two week high of $86.30. The firm’s 50 day moving average is $27.76 and its 200-day moving average is $41.38.
In other news, insider Mark W. Sawicki sold 1,410 shares of the company’s stock in a transaction that occurred on Wednesday, March 9th. The shares were sold at an average price of $31.05, for a total value of $43,780.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Robert Stefanovich sold 1,095 shares of the company’s stock in a transaction that occurred on Wednesday, March 9th. The shares were sold at an average price of $31.05, for a total transaction of $33,999.75. The disclosure for this sale can be found here. Insiders sold 5,803 shares of company stock valued at $180,183 in the last ninety days. Insiders own 9.70% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in CYRX. abrdn plc acquired a new position in shares of Cryoport in the fourth quarter valued at approximately $37,949,000. Massachusetts Financial Services Co. MA boosted its holdings in shares of Cryoport by 119.4% in the first quarter. Massachusetts Financial Services Co. MA now owns 948,578 shares of the consumer goods maker’s stock valued at $33,115,000 after buying an additional 516,197 shares during the period. Invesco Ltd. boosted its holdings in shares of Cryoport by 17.7% in the first quarter. Invesco Ltd. now owns 3,228,313 shares of the consumer goods maker’s stock valued at $112,700,000 after buying an additional 485,972 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Cryoport by 1,965.0% in the first quarter. Renaissance Technologies LLC now owns 466,700 shares of the consumer goods maker’s stock valued at $16,292,000 after buying an additional 444,100 shares during the period. Finally, Macquarie Group Ltd. boosted its holdings in shares of Cryoport by 36.4% in the third quarter. Macquarie Group Ltd. now owns 1,449,003 shares of the consumer goods maker’s stock valued at $96,373,000 after buying an additional 386,940 shares during the period.
Cryoport Company Profile (Get Rating)
Cryoport, Inc, a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle.
- Get a free copy of the StockNews.com research report on Cryoport (CYRX)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.